TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04496947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction
Description: The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being.
Study: NCT02535832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone CT Scan DXA scan Needle muscle biopsy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo CT Scan DXA scan Needle muscle biopsy
Study: NCT04003753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR App
Description: Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
Study: NCT03927638

Intervention type: BEHAVIORAL
Intervention: sit/stand
Description: Subjects will be asked to both sit and stand during a single trial.

Intervention type: BEHAVIORAL
Intervention: sit/stand
Description: Subjects will be asked to both sit and stand during a single trial.
Study: NCT02600000

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Myocardial scintigraphy
Description: Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary test
Description: Assessment of maximal functional capacity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVD-Glittre Test
Description: Evaluation of submaximal functional capacity after inspiratory muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasound
Description: Evaluation of thickness and diaphragmatic mobility
Study: NCT03777202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
Study: NCT02721134

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tubes
Description: four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
Study: NCT03657030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: SAD / MAD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: SAD / MAD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02912208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag/Revolade
Description: Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration is the same of eltrombopag
Study: NCT01896349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPT+ antidepressant drugs
Description: 16 sessions of interpersonal psychotherapy plus antidepressant drugs.
Study: NCT01452594

Intervention type: DRUG
Intervention: Diphenylcyclopropenone
Description: Topical administration

Intervention type: DRUG
Intervention: Placebo
Description: Placebo
Study: NCT02079168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04108247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone+SHR3162
Description: Participants will receive Abiraterone combined with SHR3162 orally
Study: NCT02646449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Study: NCT02839421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
Study: NCT04529447

Intervention type: OTHER
Intervention: Survey
Description: The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
Study: NCT02384694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zumba dance
Description: Twelve weeks, 3 times weekly 1 hour training
Study: NCT02794857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00206492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Description: Iressa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen
Study: NCT01524250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 1250mg of oral prednisone daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 1000mg IV methylprednisolone daily for 3 days
Study: NCT04320550

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultra sound
Description: non invasive tests to exclude pathological causes
Study: NCT00140660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 on D1
Study: NCT02278419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
Study: NCT04624347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to video and movement curves
Description: intervention of caregivers with access to videos and motion curves of the premature infant
Study: NCT03731221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupi HCI and lipo bupi
Description: The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupi HCI
Description: The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
Study: NCT04252222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with VL3
Description: Tracheal Intubation aided by VL3 Videolaryngoscope
Study: NCT03757273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFF with CAD/CAM customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFF without customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction.
Study: NCT02765217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
Study: NCT00372762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bumetanide
Description: 0.5mg to 2mg orally once or twice daily
Study: NCT03641859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain).
Study: NCT02218320

Intervention type: DRUG
Intervention: Raltegravir

Intervention type: DRUG
Intervention: Dolutegravir

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsy
Description: This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.

Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsy
Description: This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
Study: NCT04229420

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block vs Erector spinae plane block
Description: Ultrasound guided Rectus sheath block vs Erector spinae plane block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block vs Erector spinae plane block
Description: Ultrasound guided Rectus sheath block vs Erector spinae plane block
Study: NCT03777202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygen
Description: Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
Study: NCT02290964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ANH
Description: After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Study: NCT01654042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged interval between PT testing
Description: Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
Study: NCT01581684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: Medium dose solution for oral administration
Study: NCT02331615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroConn_CE_DC-STIMULATOR
Description: right frontal anodal stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroConn_CE_DC-STIMULATOR
Description: left frontal anodal stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: no meaningful stimulation will be given
Study: NCT04414839

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Intubation (Two-finger)
Description: In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy
Description: In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
Study: NCT01896349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Study: NCT03817801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSE balloon
Description: NSE (Goodman®) predilation + DCB (Sequent® Please) treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NC balloon
Description: NC balloon predilation + DCB (Sequent® Please) treatment
Study: NCT01896349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Study: NCT01581684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: High dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: High dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: Medium dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: High dose solution for oral administration
Study: NCT01896349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study: NCT03926455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhax (investigational typhoid fever candidate vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhax (investigational typhoid fever candidate vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhax (investigational typhoid fever candidate vaccine)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered to the control group on Day 0 and 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is administered to the control group on Day 0 and 28
Study: NCT01635062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 3 weeks.
Study: NCT04048941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Needle Hand Acupuncture with Movement
Description: One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Needle Hand Acupuncture without Movement
Description: One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Acupuncture with Movement
Description: Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
Study: NCT01484418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Description: 5-10 sessions based on an individualized fear hierarchy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Description: 5-10 sessions based on an individualized fear hierarchy